Tearsheet

Cyclacel Pharmaceuticals (CYCC)

Market Price (9/30/2025): $4.8 | Market Cap: $7.6 Mil
Sector: Health Care | Industry: Biotechnology

Cyclacel Pharmaceuticals (CYCC)

Market Price (9/30/2025): $4.8
Market Cap: $7.6 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -45%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -103580%
1		Expensive valuation multiples P/SPrice/Sales ratio is 954x
2		Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -87%, Rev Chg QQuarterly Revenue Change % is null
3		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -87260%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -87260%
4		Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 913%
5		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -45%
1	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -103580%
2	Expensive valuation multiples P/SPrice/Sales ratio is 954x
3	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -87%, Rev Chg QQuarterly Revenue Change % is null
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -87260%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -87260%
5	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 913%
6	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72%

Market Valuation

	9/30/25	2024	2023	2022	2021
Share Price CYE	$4.80	$42.80	$303.89	$1,138.74	$6,641.22
Market Cap CYE ($ Mil)	7.6	1.6	1.3	2.2	18.4
Total Debt ($ Mil)	0.0	0.0	0.0	0.1	0.0
Total Cash ($ Mil)	4.3	3.1	3.4	18.3	36.6
Enterprise Value ($ Mil)	3.3	1.6	1.3	2.3	18.4
Valuation Ratios
P/S TTM	760.3	46.8	5.4	0.0	0.0
P/EBIT TTM	-0.7	-0.2	-0.1	-0.2	-1.6
P/E TTM	-1.2	-0.2	-0.1	-0.3	-1.9
Sector Ratios
P/S TTM (Sector)	3.7	3.6	4.0	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.8
P/E TTM (Sector)	-1.9	-1.5	-1.5	-1.3	-2.8

	9/30/25	2024	2023
Share Price CYE	$4.80	$42.80	$303.89
Market Cap CYE ($ Mil)	7.6	1.6	1.3
Total Debt ($ Mil)	0.0	0.0	0.0
Total Cash ($ Mil)	4.3	3.1	3.4
Enterprise Value ($ Mil)	3.3	1.6	1.3
Valuation Ratios
P/S TTM	760.3	46.8	5.4
P/EBIT TTM	-0.7	-0.2	-0.1
P/E TTM	-1.2	-0.2	-0.1
Sector Ratios
P/S TTM (Sector)	3.7	3.6	4.0
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-1.9	-1.5	-1.5

Stock Price
Market Cap

Return (1M):

Business Description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
CYCC Return	-42%	-50%	-83%	-73%	-86%	-86%	-100%
Peers Return	-19%	-12%	-7%	-26%	-43%	12%	-69%
S&P 500 Return	16%	27%	-19%	24%	23%	13%	106%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ACSB, ALPS, APLM, APM.
[3] 2025 data is for the year up to 9/29/2025 (YTD)

Better Bets than Cyclacel Pharmaceuticals (CYCC)

	CYCC	Better Performance than CYCC
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	-87.5%	ABBV (6.1%), AMGN (12.9%), GILD (3.8%), VRTX (10.5%), REGN (5.4%)
Op Mgn LTM	-103580.0%	ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM	-87260.0%	ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM	-87260.0%	ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield	-67.2%	ABBV (3.8%), AMGN (7.9%), GILD (7.3%), VRTX (3.6%), REGN (7.9%)

	CYCC	Better Performance than CYCC
Metric	Value	Sector (Health Care)
Rev Chg LTM	-87.5%	LLY (36.8%), JNJ (4.7%), ABBV (6.1%), UNH (9.7%), ABT (5.9%)
Op Mgn LTM	-103580.0%	LLY (43.0%), JNJ (24.5%), ABBV (23.5%), UNH (7.3%), ABT (17.4%)
CFO/Rev LTM	-87260.0%	LLY (20.5%), JNJ (25.4%), ABBV (33.1%), UNH (6.8%), ABT (21.0%)
FCF/Rev LTM	-87260.0%	LLY (-0.1%), JNJ (18.1%), ABBV (31.3%), UNH (6.0%), ABT (15.7%)
Total Yield	-67.2%	LLY (2.9%), JNJ (8.0%), ABBV (3.8%), UNH (9.3%), ABT (7.7%)

	CYCC	Better Performance than CYCC
Metric	Value	All Other Sectors
Rev Chg LTM	-87.5%	NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Op Mgn LTM	-103580.0%	NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM	-87260.0%	NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM	-87260.0%	NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield	-67.2%	NVDA (2.0%), MSFT (3.3%), AAPL (3.0%), GOOGL (4.2%), AMZN (3.0%)

Trade Ideas

Select past trade ideas related to CYCC and Biotechnology.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE	08312025	LNTH	Lantheus	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.8%	-7.8%	-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper	08312025	COO	Cooper Companies	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.2%	0.2%	-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper	08312025	WST	West Pharmaceutical Services	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	5.9%	5.9%	-1.3%
BMY_7312025_Dip_Buyer_FCFYield	07312025	BMY	Bristol-Myers Squibb	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	1.9%	1.9%	0.0%
UTHR_7312025_Dip_Buyer_FCFYield	07312025	UTHR	United Therapeutics	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	57.5%	57.5%	0.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE	08312025	LNTH	Lantheus	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.8%	-7.8%	-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper	08312025	COO	Cooper Companies	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.2%	0.2%	-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper	08312025	WST	West Pharmaceutical Services	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	5.9%	5.9%	-1.3%
BMY_7312025_Dip_Buyer_FCFYield	07312025	BMY	Bristol-Myers Squibb	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	1.9%	1.9%	0.0%
UTHR_7312025_Dip_Buyer_FCFYield	07312025	UTHR	United Therapeutics	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	57.5%	57.5%	0.0%

See Trefis Trade Ideas for more.

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	WOLF	Wolfspeed	1726.4%	231.8%
2	BQ	Boqii	233.2%	153.9%
3	YCBD	cbdMD	121.2%	-54.0%
4	ENTA	Enanta Pharmaceuticals	91.9%	163.7%
5	JFB	JFB Construction	85.4%
6	TLRY	Tilray Brands	60.9%	39.1%
7	POAI	Predictive Oncology	54.8%	46.3%
8	SCOR	comScore	46.2%	53.3%
9	DWTX	Dogwood Therapeutics	43.3%	217.7%
10	BKKT	Bakkt	42.3%	3.1%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	MLTX	MoonLake Immunotherapeutics	-89.9%	-88.5%
2	KALA	Kala Bio	-89.3%	-70.5%
3	IOBT	IO Biotech	-76.9%	-60.3%
4	JZXN	Jiuzi	-60.3%	-69.5%
5	APLT	Applied Therapeutics	-50.7%	-28.5%
6	MTEK	Maris Tech	-50.6%	-58.9%
7	BIAF	bioAffinity Technologies	-38.6%	-88.1%
8	MTEN	Mingteng International	-38.0%	0.0%
9	BYND	Beyond Meat	-36.1%	-51.6%
10	LRMR	Larimar Therapeutics	-33.7%	-12.7%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	FTEL	Fitell	1068.4%	-96.0%
2	WOLF	Wolfspeed	886.6%	231.8%
3	WHLR	Wheeler Real Estate Investment Trust	404.4%	-99.7%
4	MNDR	Mobile-health Network Solutions	388.0%	-71.1%
5	QURE	uniQure	329.5%	236.4%
6	NUAI	New Era Energy & Digital	311.7%
7	BQ	Boqii	208.5%	153.9%
8	DVLT	Datavault AI	180.5%
9	DFLI	Dragonfly Energy	132.9%	-76.4%
10	SHFS	SHF	130.9%	-18.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	WOK	WORK Medical Technology	-91.5%	-98.5%
2	KALA	Kala Bio	-89.0%	-70.5%
3	MLTX	MoonLake Immunotherapeutics	-88.6%	-88.5%
4	SDM	Smart Digital	-87.5%	-83.8%
5	NRIM	Northrim BanCorp	-76.1%	14.0%
6	IOBT	IO Biotech	-75.5%	-60.3%
7	ZYBT	Zhengye Biotechnology	-74.9%
8	AMBI	Ambipar Emergency Response	-74.0%	-78.8%
9	FGL	Founder	-63.8%	-64.3%
10	BINI	Bollinger Innovations	-63.6%	-100.0%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	13709.5%	13709.5%
2	TNFA	TNF Pharmaceuticals	7529.9%	-95.9%
3	QMMM	QMMM	2749.6%	9228.1%
4	WOLF	Wolfspeed	1757.1%	231.8%
5	EAF	GrafTech International	1199.0%	-24.2%
6	SEGG	Lottery.com	646.7%	-7.9%
7	SLNH	Soluna	435.8%	20.0%
8	PTNM	Pitanium	433.3%
9	NUAI	New Era Energy & Digital	395.6%
10	BREA	Brera	380.3%	3593.8%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	BINI	Bollinger Innovations	-96.1%	-100.0%
2	WOK	WORK Medical Technology	-90.8%	-98.5%
3	CJET	Chijet Motor	-90.3%	-92.7%
4	MLTX	MoonLake Immunotherapeutics	-88.6%	-88.5%
5	YAAS	Youxin Technology	-85.8%	-98.9%
6	ATYR	aTyr Pharma	-85.1%	-78.0%
7	CURX	Curanex Pharmaceuticals	-84.9%	28.8%
8	YYGH	YY	-84.6%	-80.3%
9	NEON	Neonode	-84.6%	-58.7%
10	SDM	Smart Digital	-82.5%	-83.8%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	WOLF	Wolfspeed	1726.4%	231.8%
2	BQ	Boqii	233.2%	153.9%
3	YCBD	cbdMD	121.2%	-54.0%
4	ENTA	Enanta Pharmaceuticals	91.9%	163.7%
5	JFB	JFB Construction	85.4%
6	TLRY	Tilray Brands	60.9%	39.1%
7	POAI	Predictive Oncology	54.8%	46.3%
8	SCOR	comScore	46.2%	53.3%
9	DWTX	Dogwood Therapeutics	43.3%	217.7%
10	BKKT	Bakkt	42.3%	3.1%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	MLTX	MoonLake Immunotherapeutics	-89.9%	-88.5%
2	KALA	Kala Bio	-89.3%	-70.5%
3	IOBT	IO Biotech	-76.9%	-60.3%
4	JZXN	Jiuzi	-60.3%	-69.5%
5	APLT	Applied Therapeutics	-50.7%	-28.5%
6	MTEK	Maris Tech	-50.6%	-58.9%
7	BIAF	bioAffinity Technologies	-38.6%	-88.1%
8	MTEN	Mingteng International	-38.0%	0.0%
9	BYND	Beyond Meat	-36.1%	-51.6%
10	LRMR	Larimar Therapeutics	-33.7%	-12.7%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	FTEL	Fitell	1068.4%	-96.0%
2	WOLF	Wolfspeed	886.6%	231.8%
3	WHLR	Wheeler Real Estate Investment Trust	404.4%	-99.7%
4	MNDR	Mobile-health Network Solutions	388.0%	-71.1%
5	QURE	uniQure	329.5%	236.4%
6	NUAI	New Era Energy & Digital	311.7%
7	BQ	Boqii	208.5%	153.9%
8	DVLT	Datavault AI	180.5%
9	DFLI	Dragonfly Energy	132.9%	-76.4%
10	SHFS	SHF	130.9%	-18.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	WOK	WORK Medical Technology	-91.5%	-98.5%
2	KALA	Kala Bio	-89.0%	-70.5%
3	MLTX	MoonLake Immunotherapeutics	-88.6%	-88.5%
4	SDM	Smart Digital	-87.5%	-83.8%
5	NRIM	Northrim BanCorp	-76.1%	14.0%
6	IOBT	IO Biotech	-75.5%	-60.3%
7	ZYBT	Zhengye Biotechnology	-74.9%
8	AMBI	Ambipar Emergency Response	-74.0%	-78.8%
9	FGL	Founder	-63.8%	-64.3%
10	BINI	Bollinger Innovations	-63.6%	-100.0%

Peer Comparisons for Cyclacel Pharmaceuticals

Financials

	CYCC	VRTX	ACSB	ALPS	APLM	APM	Median
Name	Cyclacel.	Vertex P.	Acesis	ALPS	Apollomi.	Aptorum
Mkt Price	-	395.31	-	-	-	1.82	198.56
Mkt Cap	0.0	101.5	-	-	-	-	50.7
Rev LTM	0	11,419	-	-	-	-	5,709
Op Inc LTM	-10	-199	-	-	-	-	-105
FCF LTM	-9	3,500	-	-	-	-	1,745
FCF 3Y Avg	-14	1,984	-	-	-	-	985
CFO LTM	-9	3,846	-	-	-	-	1,919
CFO 3Y Avg	-14	2,324	-	-	-	-	1,155

Growth & Margins

	CYCC	VRTX	ACSB	ALPS	APLM	APM	Median
Name	Cyclacel.	Vertex P.	Acesis	ALPS	Apollomi.	Aptorum
Rev Chg LTM	-87.5%	10.5%	-	-	-	-	-38.5%
Rev Chg 3Y Avg	-	11.0%	-	-	-	-	11.0%
Rev Chg Q	-100.0%	12.1%	-	-	-	-	-44.0%
QoQ Delta Rev Chg LTM	-28.6%	2.9%	-	-	-	-	-12.8%
Op Mgn LTM	-103,580.0%	-1.7%	-	-	-	-	-51,790.9%
Op Mgn 3Y Avg	-45,497.3%	26.5%	-	-	-	-	-22,735.4%
QoQ Delta Op Mgn LTM	-12,972.9%	2.0%	-	-	-	-	-6,485.4%
CFO/Rev LTM	-87,260.0%	33.7%	-	-	-	-	-43,613.2%
CFO/Rev 3Y Avg	-35,698.1%	22.5%	-	-	-	-	-17,837.8%
FCF/Rev LTM	-87,260.0%	30.6%	-	-	-	-	-43,614.7%
FCF/Rev 3Y Avg	-35,698.7%	19.2%	-	-	-	-	-17,839.7%

Valuation

	CYCC	VRTX	ACSB	ALPS	APLM	APM	Median
Name	Cyclacel.	Vertex P.	Acesis	ALPS	Apollomi.	Aptorum
Mkt Cap	0.0	101.5	-	-	-	-	50.7
P/S	953.5	8.9	-	-	-	-	481.2
P/EBIT	-0.9	23.1	-	-	-	-	11.1
P/E	-1.5	27.9	-	-	-	-	13.2
P/CFO	-1.1	26.4	-	-	-	-	12.6
Total Yield	-67.2%	3.6%	-	-	-	-	-31.8%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-259.9%	2.1%	-	-	-	-	-128.9%
D/E	0.0	0.0	-	-	-	-	0.0
Net D/E	-0.4	-0.0	-	-	-	-	-0.2

Returns

	CYCC	VRTX	ACSB	ALPS	APLM	APM	Median
Name	Cyclacel.	Vertex P.	Acesis	ALPS	Apollomi.	Aptorum
1M Rtn	-	1.1%	-	-	-	-7.6%	-3.3%
3M Rtn	-	-11.2%	-	-	-	100.0%	44.4%
6M Rtn	-	-18.5%	-	-	-	116.7%	49.1%
12M Rtn	-	-14.6%	-	-	-	-1.6%	-8.1%
3Y Rtn	-	36.5%	-	-	-	-84.2%	-23.8%
1M Excs Rtn	-	-1.6%	-	-	-	-20.3%	-11.0%
3M Excs Rtn	-	-18.6%	-	-	-	92.6%	37.0%
6M Excs Rtn	-	-39.1%	-	-	-	86.3%	23.6%
12M Excs Rtn	-	-30.8%	-	-	-	-28.1%	-29.4%
3Y Excs Rtn	-	-39.2%	-	-	-	-161.3%	-100.2%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/14/2025	4/2/2025	3/21/2024	3/8/2023	3/30/2022	3/1/2021	3/5/2020
Key Financials
Total Revenue	0	0	0	0	0	0	0
EBITDA	-10	-12	-25	-28	-22	-11	-10
Operating Income	-10	-12	-25	-28	-22	-11	-10
Net Income	-6	-11	-23	-21	-18	-8	-8
EPS	-137.10	-501.60	-6420.00	-6888.00	-7524.00	-12312.00	-33743.70
Growth Rates
Total Revenue Growth	-87.5%	-89.8%	∞%	-	-	-	-100.0%
EBITDA Growth	48.4%	52.8%	8.0%	-23.6%	-110.5%	-9.9%	-1.5%
Operating Income Growth	48.7%	52.8%	8.0%	-23.5%	-110.5%	-9.9%	-1.4%
Net Income Growth	63.4%	50.3%	-6.4%	-14.9%	-118.6%	-7.9%	-7.4%
Margins
EBITDA Margin	-104130.0%	-27902.3%	-6052.9%	-	-	-	-
Operating Income Margin	-103580.0%	-27916.3%	-6060.2%	-	-	-	-
Net Income Margin	-64080.0%	-26074.4%	-5370.2%	-	-	-	-
Cash & Debt
Total Cash	4	3	3	18	37	33	12
Total Debt	0	0	0	0	0	1	1
Net Debt / (Cash)	-4	-3	-3	-18	-37	-32	-11
Cash Flows
Net Cash from Operations	-9	-8	-16	-21	-19	-8	-9
Free Cash from Operations	-9	-8	-16	-21	-19	-8	-9
Returns to Shareholders
Dividends	0	-0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/14/2025	5/14/2025	4/2/2025	11/12/2024	8/14/2024	5/14/2024	3/21/2024	11/29/2023	8/10/2023	5/11/2023	3/8/2023	11/10/2022
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-1	-5	-2	-2	-4	-4	-5	-7	-6	-7	-9	-6
Operating Income	-1	-5	-2	-2	-4	-4	-5	-7	-6	-7	-9	-6
Net Income	-1	-0	-3	-2	-3	-3	-5	-6	-5	-6	-7	-5
EPS	-14.70	0.00	-79.20	-43.20	-2582.70	-544.80	-1495.20	-115.20	-1576.80	-1680.00	-2160.00	-1548.00
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda TTM	-10	-13	-12	-16	-20	-22	-25	-29	-29	-28	-28	-25
Operating Income TTM	-10	-13	-12	-16	-20	-22	-25	-29	-29	-28	-28	-25
Net Income TTM	-6	-8	-11	-13	-18	-20	-23	-25	-24	-23	-21	-19
Growth Rates Quarterly
Total Revenue Growth	-100.0%	-100.0%	-100.0%	-37.5%	-98.9%	-	-	-	-	-	-	-
EBITDA Growth	63.8%	-15.7%	64.8%	68.2%	38.5%	40.5%	39.4%	-5.9%	-2.5%	-11.6%	-47.8%	-7.9%
Operating Income Growth	63.9%	-15.6%	65.9%	68.2%	38.5%	40.5%	39.4%	-5.8%	-2.5%	-11.6%	-47.8%	-7.8%
Net Income Growth	59.5%	97.3%	42.1%	67.6%	40.2%	49.2%	29.0%	-18.4%	-19.1%	-41.3%	-52.5%	-2.2%
Margins Quarterly
EBITDA Margin	-	-	-	-21760.0%	-90975.0%	-15010.3%	-17264.5%	-42737.5%	-1587.4%	-	-	-
Operating Income Margin	-	-	-	-21770.0%	-91100.0%	-15017.2%	-17290.3%	-42781.2%	-1589.5%	-	-	-
Net Income Margin	-	-	-	-19570.0%	-81425.0%	-10158.6%	-17003.2%	-37700.0%	-1460.6%	-	-	-
Cash & Debt
Total Cash	4	3	3	3	6	3	3	6	10	11	18	24
Total Debt	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt / (Cash)	-4	-3	-3	-3	-6	-3	-3	-6	-10	-11	-18	-24
Cash Flows Quarterly
FCF from Operations	-1	-3	-1	-3	-3	-0	-4	-4	-1	-7	-5	-7
Cash Flows TTM
FCF from Operations TTM	-9	-11	-8	-11	-12	-10	-16	-17	-20	-21	-21	-20
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-1.2%	-4.6%	-1.7%	-1.8%	-3.0%	-2.8%	-4.7%	-5.8%	-5.1%	-5.7%	-7.1%	-5.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-2.3%	-2.9%	-2.6%	-3.0%	-4.0%	-4.6%	-5.3%	-5.9%	-5.8%	-5.6%	-5.5%	-5.0%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and	0	0	0
Total	0	0	0

Operating Income by Segment

$ Mil	2024	2023	2022	2021	2020
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and	-25
Total	-25

Net Income by Segment

$ Mil	2024	2023	2022	2021	2020
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and	-23
Total	-23

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and		28	43	37	15
Total		28	43	37	15

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$6.02
Market Cap ($ Bil)	0.0
First Trading Date	05/05/2004
Distance from 52W High	-96.3%
	50 Days	200 Days
DMA Price	$8.53	$27.74
DMA Trend	down	up
Distance from DMA	-29.4%	-78.3%
	3M	1YR
Volatility	639.8%	351.7%
Downside Capture	-1057.34	98.08
Upside Capture	-459.49	-219.40
Correlation (SPY)	-8.2%	1.3%

CYCC Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	2.00	-7.67	-7.17	0.25	0.22	0.23
Up Beta	-0.01	3.46	-1.92	0.84	0.59	0.49
Down Beta	10.41	4.59	1.74	2.72	1.86	1.10
Up Capture	-130%	-331%	-351%	-92%	-50%	-5%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	7	15	25	51	102	311
Down Capture	392%	-2778%	-352%	8%	81%	99%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	14	27	38	74	143	421

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/13/2025	-0.1%	-17.8%	-32.4%
4/2/2025	-6.2%	-7.4%	116.0%
11/12/2024	9.8%	-8.9%	-10.7%
8/14/2024	-9.0%	-15.9%	-30.3%
3/19/2024	-4.3%	-18.3%	-21.3%
11/13/2023	-35.5%	-42.4%	-53.2%
8/9/2023	-0.4%	-15.0%	-44.2%
3/6/2023	-2.6%	-15.0%	-23.8%
...
SUMMARY STATS
# Positive	5	5	8
# Negative	15	15	12
Median Positive	3.0%	11.8%	16.6%
Median Negative	-3.1%	-9.3%	-31.4%
Max Positive	26.3%	51.1%	116.0%
Max Negative	-35.5%	-42.4%	-53.2%

	Forward Returns
8/13/2025	-0.1%	-17.8%	-32.4%
4/2/2025	-6.2%	-7.4%	116.0%
11/12/2024	9.8%	-8.9%	-10.7%
8/14/2024	-9.0%	-15.9%	-30.3%
3/19/2024	-4.3%	-18.3%	-21.3%
11/13/2023	-35.5%	-42.4%	-53.2%
8/9/2023	-0.4%	-15.0%	-44.2%
3/6/2023	-2.6%	-15.0%	-23.8%
11/9/2022	-1.7%	-9.3%	-39.7%
8/10/2022	26.3%	51.1%	26.3%
3/28/2022	2.5%	-2.5%	-39.0%
11/10/2021	-1.0%	-8.4%	-30.2%
8/11/2021	-3.4%	-7.1%	7.5%
5/12/2021	3.0%	18.1%	10.2%
2/25/2021	-1.4%	-12.9%	5.7%
11/12/2020	-1.1%	1.1%	23.1%
8/12/2020	-5.5%	-4.4%	-27.4%
5/12/2020	2.2%	5.8%	7.5%
2/26/2020	-11.3%	-8.6%	-34.6%
11/13/2019	-3.1%	11.8%	62.8%
SUMMARY STATS
# Positive	5	5	8
# Negative	15	15	12
Median Positive	3.0%	11.8%	16.6%
Median Negative	-3.1%	-9.3%	-31.4%
Max Positive	26.3%	51.1%	116.0%
Max Negative	-35.5%	-42.4%	-53.2%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8142025	10-Q 6/30/2025
3312025	5142025	10-Q 3/31/2025
12312024	4022025	10-K 12/31/2024
9302024	11122024	10-Q 9/30/2024
6302024	8142024	10-Q 6/30/2024
3312024	5142024	10-Q 3/31/2024
12312023	3212024	10-K 12/31/2023
9302023	11292023	10-Q 9/30/2023
6302023	8102023	10-Q 6/30/2023
3312023	5112023	10-Q 3/31/2023
12312022	3082023	10-K 12/31/2022
9302022	11102022	10-Q 9/30/2022
6302022	8112022	10-Q 6/30/2022
3312022	5122022	10-Q 3/31/2022
12312021	3302022	10-K 12/31/2021
9302021	11122021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Lazar David E.		8042025	Sell	12.36	6,750	83,430	1,926,158	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Cyclacel Pharmaceuticals (CYCC)

Market Price (9/30/2025): $4.8 | Market Cap: $7.6 MilSector: Health Care | Industry: Biotechnology

Cyclacel Pharmaceuticals (CYCC)

Market Price (9/30/2025): $4.8Market Cap: $7.6 MilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Cyclacel Pharmaceuticals (CYCC)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Cyclacel Pharmaceuticals

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/30/2025): $4.8 | Market Cap: $7.6 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (9/30/2025): $4.8
Market Cap: $7.6 Mil
Sector: Health Care
Industry: Biotechnology